Aerosolized terbutaline sulfate in the treatment of bronchospasm
Scoggin, C.H.
Clinical Therapeutics 6(5): 603-612
1984
ISSN/ISBN: 0149-2918 PMID: 6434183 Document Number: 221680
Terbutaline sulfate, a relatively selective .beta.2 agonist, is indicated for the treatment of bronchospasm associated with chronic obstructive pulmonary disease. Studies have shown that when administered via an aerosol, terbutaline has a rapid onset, a prolonged duration of action, and a low incidence of systemic side effects. Because the drug is delivered directly to the bronchi, low doses of aerosolized terbutaline can be administered and achieve a bronchodilatory effect can be achieved comparable to that achieved with higher doses of the oral form.